Single User
£3750
PDF
46 pages

Uveitis Forecast in 10 Major Markets 2015-2025


Uveitis is a general term associated with a group of inflammatory conditions that produce swelling and causes injury to the eye. The cause of Uveitis varies greatly in respect to the geography. The main causes include that of infectious agents or linked to systemic autoimmune diseases. In this report the infectious and immune causes of Uveitis are examined. This report provides the current prevalent population for Uveitis across 10 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, China and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors and prevention, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Uveitis have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Uveitis include:

  • Autoimmune diseases (systemic)
  • Ocular hypertension
  • Macular oedema
  • Reduction in visual acuity
  • Presence of epiretinal membranes
  • Diabetes mellitus
  • Tuberculosis

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Uveitis’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of Uveitis and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Useful in the identification and trend of the prevalence numbers for the different causative agents of Uveitis.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Uveitis’s prevalent population.
  • Identify sub-populations within Uveitis which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Uveitis patients.

Table of Contents

  • List of Tables & Figures
  • Overview
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Standardisation of Uveitis Nomenclature (SUN) Working Group Guidelines
  • Key Co-morbid Conditions Associated with the Disease
  • Methodology for Quantification of Patient Numbers
  • Top-Line Uveitis Prevalence
  • Uveitis by Anatomical Location in the Eye
  • Aetiology of Uveitis
    • Anterior Uveitis
    • Intermediate Uveitis
    • Posterior Uveitis
  • Infectious Causes of Uveitis
  • Co-morbid Ophthalmic Conditions for Uveitis
  • References
  • Appendix

List of Tables & Figures

  • The SUN Working Group Anatomic Classification of Uveitis (000s)
  • The SUN Working Group Descriptors of Uveitis (000s)
  • Prevalence of Uveitis, total (000s)
  • Prevalence of Uveitis, males (000s)
  • Prevalence of Uveitis, females (000s)
  • Uveitis by anatomical site, total (000s)
  • Aetiology of anterior uveitis, total (000s)
  • Duration of attack for anterior uveitis, total (000s)
  • Aetiology of intermediate uveitis, total (000s)
  • Aetiology of posterior uveitis, total (000s)
  • Aetiology of panuveitis, total (000s)
  • Infectious uveitis by casual agent, total (000s)
  • Prevalence of ocular hypertension within uveitis patients, total (000s)
  • Prevalence of macular oedema within uveitis patients, total (000s)
  • Prevalence of epiretinal membranes within uveitis patients, total (000s)
  • USA Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • USA Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • France Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • France Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • Germany Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Germany Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • Italy Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Italy Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • Spain Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Spain Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • Brazil Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Brazil Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • China Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Japan Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • Japan Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • China Prevalence of Uveitis by 5-yr age cohort, females (000s)
  • India Prevalence of Uveitis by 5-yr age cohort, males (000s)
  • India Prevalence of Uveitis by 5-yr age cohort, females (000s)
Brazil, China, France, Germany, India, Italy, Japan, Spain, United Kingdom, United States of America